Presented at: AACR 2020
You are currently viewing a placeholder content from HubSpot. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationRelevant for
FixVUE, InSituPlex
Presented at: AACR 2020
You are currently viewing a placeholder content from HubSpot. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationRelevant for
Collaboration, FixVUE, InSituPlex
Presented at: AACR 2020
You are currently viewing a placeholder content from HubSpot. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationRelevant for
Collaboration, InSituPlex
You are currently viewing a placeholder content from HubSpot. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationRelevant for
Collaboration, FixVUE, InSituPlex
Description Profiling multiple cell types in tissue samples requires more markers than can be supported by conventional approaches to immunohistochemistry. InSituPlex® multipleximmunofluorescence (mIF) technology enables biomarker multiplexing int issue samples with an automated workflow to support discovery of immunecell signatures in the tumor immunemicroenvironment (TiME).Here we have designed and tested an 8- plex immuno phenotyping panel using the InSituPlex® approach to detect and classify T cells, macrophages, and tumor cell in non- small cell lung cancer (NSCLC) and colorectal cancer (CRC) FFPE tissue.
Anne Hellebust, Kyla Teplitz, Katir K Patel, Karan Sharma, Amanda Bares, Mael Manesse, Mark Burton, Bonnie Phillips, Sean Downing and Kate Lillard
Presented at: AACR 2020
You are currently viewing a placeholder content from HubSpot. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationRelevant for
FixVUE, InSituPlex
Douglas Wood, Heike Boisvert, Sean R. Downing and Maël Manesse
Presented at: AACR 2020
You are currently viewing a placeholder content from HubSpot. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationRelevant for
Collaboration, FixVUE, InSituPlex
Douglas Wood, Heike Boisvert, Sean R. Downing and Maël Manesse
You are currently viewing a placeholder content from HubSpot. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationRelevant for
Collaboration, FixVUE, InSituPlex
Description Profiling multiple cell types in tissue samples requires more markers than can be supported by conventional approaches to immunohistochemistry. InSituPlex® multipleximmunofluorescence (mIF) technology enables biomarker multiplexing int issue samples with an automated workflow to support discovery of immunecell signatures in the tumor immunemicroenvironment (TiME).Here we have designed and tested an 8- plex immuno phenotyping panel using the InSituPlex® approach to detect and classify T cells, macrophages, and tumor cell in non- small cell lung cancer (NSCLC) and colorectal cancer (CRC) FFPE tissue.
You are currently viewing a placeholder content from Facebook. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Instagram. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from X. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information
H&E
5859
Measuring concordance of CD8 and PD-L1 expression in Non-Small Cell Lung cancer between a novel multiplex immunofluorescence assay and a brightfield laboratory developed test
